Yu-Tong Hu
Yue-Nan Ni
Hugi Hilmisson3
Robert Joseph Thomas- 1Department of Respiratory, Critical Care and Sleep Medicine, West China School of Medicine and West China Hospital, Sichuan University, Chengdu, China
- 2Department of Respiratory Care, West China School of Medicine and West China Hospital, Sichuan University, Chengdu, China
- 3MyCardio-LLC, Denver, CO, United States
- 4Division of Pulmonary, Critical Care and Sleep Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United States
by Hu, Y.-T., Ni, Y.-N., Hilmisson, H., and Thomas, R. J. (2025). Front. Neurosci. 19:1619467. doi: 10.3389/fnins.2025.1619467
The title of this article was erroneously given as: “Pathological respiratory chemoreflex activation predicts improvement of neurocognitive function in response to contimuous positive airway pressure therapy”. The correct title of the article is “Pathological respiratory chemoreflex activation predicts improvement of neurocognitive function in response to continuous positive airway pressure therapy.”
An extraneous period was present after the citation “(Lv et al., 2023).”
A correction has been made to the section Background, second paragraph:
“Continuous positive airway pressure (CPAP), which is regarded as the first line therapy for OSA, can improve hypoxia in OSA patients, reduce sleep fragmentation, and reverse sympathetic nerve excitation (Patil et al., 2019), but there is controversy regarding whether CPAP can improve cognitive dysfunction caused by OSA (Bucks et al., 2013). The existence of complex pathologies especially high loop gain maybe a reason for the failure due to impairment in both effectiveness and adherence (Ni and Thomas, 2023; Cheng et al., 2024). It is also plausible that pathological respiratory chemoreflex activation and the resulting heightened sympathetic activation and other pleotrophic effects such as oxidative stress, inflammatory response, and neuronal damage (Lv et al., 2023) may influence development of neurocognitive dysfunction, and response to treatment.”
The word “imfluences” was misspelled.
A correction has been made to the section Background, fourth paragraph:
“As described in our previous work, narrow band elevated low frequency coupling (e-LFCNB) measured by cardiopulmonary coupling sleep spectrograms is a biomarker indicating periodic breathing and central sleep apnea (Thomas et al., 2007), indicating high loop gain. Our previous study showed that e-LFCNB was a strong predictor for blood pressure dropping after CPAP in OSA (Ni et al., 2024). However, whether it influences neurocognitive function improvement by CPAP is not known.”
The original version of this article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: sleep apnea, positive airway pressure, cardiopulmonary coupling, neurocognitive function, high loop gain
Citation: Hu Y-T, Ni Y-N, Hilmisson H and Thomas RJ (2025) Correction: Pathological respiratory chemoreflex activation predicts improvement of neurocognitive function in response to continuous positive airway pressure therapy. Front. Neurosci. 19:1714129. doi: 10.3389/fnins.2025.1714129
Received: 27 September 2025; Accepted: 29 September 2025;
Published: 13 October 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Hu, Ni, Hilmisson and Thomas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yue-Nan Ni, dml2aWFuOTQwMzA1QGZveG1haWwuY29t